Children with type 2 diabetes in the UK who have to undergo the stressful chore of monitoring blood glucose with multiple finger prick blood tests every day could soon see
Patients in England and Wales with active lupus nephritis will soon be able to access treatment with Otsuka Pharma’s Lupkynis following a recommendation by the health tech
A pair of new guidance documents from UK cost-effectiveness authority NICE could see hundreds of more blood cancer patients eligible for treatment with CAR-T therapies fro
Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc
AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed
Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t